Abstract 456P
Background
As mentioned by ESMO guidelines on the management of constipation in advanced cancer, combined opiate/naloxone medications have been shown to reduce the risk of OIC through a range of studies. Oxycodone/naloxone prolonged-release tablets (OXN PR) provide similar efficacy, but an improved bowel function compared with oxycodone prolonged-release tablets (OXY PR). This is the first Chinese study about OXN PR in cancer pain population.
Methods
This multi-center, randomized, double-blind controlled trial compared OXN PR to OXY PR for 4 weeks in adult cancer patients with moderate-to-severe pain and OIC. Primary efficacy endpoints: Bowel Function Index (BFI) and Brief Pain Inventory-Short Form (BPI-SF). Key secondary endpoints: use of laxative (bisacodyl tablets) and rescue analgesia (morphine sulfate), quality of life (EQ-5D) and safety.
Results
232 patients were randomized (117 in the OXN PR group; 115 in the OXY PR group). BPI-SF average pain was comparable after 4 weeks between OXN PR and OXY PR groups. The difference of average BFI at 4 weeks was not statistically significant between the 2 treatment groups (FAP, p=0.482). Compared to baseline, a BFI reduction was seen after 1 week in OXN PR group (13.5 points vs. 8.8 points in OXY PR group; p=0.039). Results of an exploratory post-hoc analysis confirmed these findings, with the BFI difference favoring OXN PR. Laxative use was similar between the 2 groups, but a higher percentage of patients required laxatives in OXY PR group compared to OXN PR group at all visits. Average daily dose and percentage of patients taking rescue analgesia were similar at 4 weeks. EQ-5D assessment showed a minor improvement in the OXN PR group and a decline in OXY PR group (non-significant). Fewer adverse events were reported in the OXN PR group (17.5% vs. 27.0% in the OXY PR group); No treatment-related SAEs were reported with OXN PR group.
Conclusions
In managing moderate-to-severe cancer pain among Chinese patients, OXN PR has demonstrated comparable efficacy to OXY PR. Improvements of bowel function were numerically observed and statistically confirmed by a post-hoc analysis (p=0.039). This study adds to the wealth of evidence around the positive benefit/risk profile of OXN PR in an Asian population.
Clinical trial identification
NCT00513656.
Editorial acknowledgement
Editorial assistance was provided by MedAcc Technology Co., Ltd.
Legal entity responsible for the study
Mundipharma (China) Pharmaceutical Co.LTD.
Funding
Mundipharma (China) Pharmaceutical Co.LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract